Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1992/007982external-prioritypatent/WO1993005811A1/en
Application filed by Amgen IncfiledCriticalAmgen Inc
Publication of NO931821D0publicationCriticalpatent/NO931821D0/en
Publication of NO931821LpublicationCriticalpatent/NO931821L/en
Høyimmunogent hepatitt B-vaksine-preparat som omfatter HBsAg fremstilt som resultatet av rekombinant gjær-vertscelleekspresjon, og et gallesalt, særlig natriumdeoksycholat, samt fremgangsmåter anvendt til å fremstille vaksinen. Disse fremgangsmåtene omfatter nye gjærdyrkingsbetingelser og nye fremgangsmåter for HBsAg-rensing og tilsetning av hjelpestoffer. Fremgangsmåter hvor disse nye HBsAg-preparater benyttes til å immunisere pattedyr, særlig mennesker, som er mottakelige for hepatitt B-infeksjon.Highly immunogenic hepatitis B vaccine composition comprising HBsAg prepared as a result of recombinant yeast host cell expression, and a bile salt, especially sodium deoxycholate, as well as methods used to prepare the vaccine. These methods include new yeast culture conditions and new methods for HBsAg purification and addition of excipients. Methods using these new HBsAg preparations to immunize mammals, especially humans, susceptible to hepatitis B infection.
NO93931821A1991-09-181993-05-19
Hepatitis B Vaccine Preparation Containing A Bile Acid Salt
NO931821L
(en)